Management of Measles Exposure in Pregnancy

Immediate Assessment and Intervention

The American College of Obstetricians and Gynecologists recommends administering immune globulin (IG) at 0.25 mL/kg intramuscularly (maximum 15 mL) immediately if the pregnant woman has no evidence of measles immunity and the exposure occurred within the past 6 days, as IG is the only appropriate intervention for this population 1, 2
If within 72 hours of exposure, MMR vaccine would typically be the preferred post-exposure prophylaxis for non-pregnant individuals, but MMR vaccine is absolutely contraindicated in pregnancy due to theoretical teratogenic risks from live virus administration, according to the Centers for Disease Control and Prevention 3, 2

The Centers for Disease Control and Prevention recommends monitoring for measles symptoms for 21 days after exposure, with key symptoms including fever, cough, coryza, conjunctivitis, followed by characteristic maculopapular rash starting on face and spreading cephalocaudally 4

The American College of Obstetricians and Gynecologists recommends administering MMR vaccine before hospital discharge if the woman remains non-immune and has no other contraindications, as postpartum vaccination is critical and could prevent approximately 40% of congenital rubella syndrome cases 5, 6
The Centers for Disease Control and Prevention states that breastfeeding is not a contraindication to MMR vaccination 5, 3
If IG was administered during pregnancy, the American College of Obstetricians and Gynecologists recommends delaying MMR vaccination until 5-6 months after IG administration to avoid interference with vaccine immunogenicity from passively acquired antibodies 1, 2, 7

The Centers for Disease Control and Prevention advises never administering MMR vaccine during pregnancy, even within 72 hours of exposure—IG is the only option for pregnant women, with a strength of evidence classified as high 3, 2
The American College of Obstetricians and Gynecologists warns against confusing measles (rubeola) with rubella (German measles)—they are different diseases with different risks; IG is not indicated for rubella exposure, with a strength of evidence classified as moderate 1, 2

The Centers for Disease Control and Prevention (CDC) recommends that any postpartum woman lacking documented immunity receive a single dose of MMR before hospital discharge, irrespective of breastfeeding status or receipt of blood products during pregnancy or delivery. 8
Immediate postpartum vaccination of non‑immune women is estimated to prevent approximately 40–50 % of future congenital rubella syndrome cases. 8
If a woman has received anti‑Rho(D) immunoglobulin or other blood products in the third trimester or at delivery, the CDC advises that MMR be administered immediately after birth despite potential interference with the immune response. 9

Acceptable proof of immunity includes recorded prior MMR vaccination or serologic confirmation of rubella immunity. 8

When MMR is given after exposure to blood products, the CDC recommends repeat serologic testing at ≥ 3 months post‑vaccination to verify development of measles and rubella antibodies. 9

Women should be counseled to avoid conception for at least 3 months (or 28 days according to newer CDC guidance) after receiving MMR, to mitigate theoretical risks of live‑virus exposure to the fetus. 8

Postpartum women born outside the United States, particularly of Hispanic origin, require targeted attention because recent rubella outbreaks have occurred in these groups, indicating a higher likelihood of non‑immunity. 8

Severe immunosuppression (e.g., primary immunodeficiency, leukemia, lymphoma, generalized malignancy, or therapy with high‑dose corticosteroids, alkylating agents, antimetabolites, or radiation) is an absolute contraindication to MMR vaccination. 9
A history of anaphylaxis to egg proteins or neomycin (manifesting as urticaria, oral/pharyngeal edema, respiratory distress, hypotension, or shock) constitutes an absolute contraindication. 10